BPMC News and Press, Blueprint Medicines Corporation From 09/25/20

As expected, the European Commission approves Blueprint Medicines' ([[BPMC]] -0.7%) Ayvakyt (avapritinib) as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors ((GIST)) harboring the platelet-derived growth factor receptor alpha ((P...

Blueprint Medicines Announces European Commission Approval of AYVAKYT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors -- First highly effective treatment option approved in Europe for PDGFRA D842...

Blueprint Medicines (BPMC) +3.8% in premarket, has announced top-line data from the Phase 1 EXPLORER and Phase 2 PATHFINDER clinical trials of AYVAKIT (avapritinib) in patients with advanced systemic mastocytosis ((SM)).In the EXPLORER trial, 53 patients were response evaluable, wit...

Blueprint Medicines Announces Positive Top-line Results from EXPLORER and PATHFINDER Trials of AYVAKIT™ (avapritinib) in Patients with Advanced Systemic Mastocytosis -- 76% confirmed ORR in EXPLORER, with a median duration of response of 38.3 months -- -- 75% confirme...

CAMBRIDGE, Mass. , Sept. 20, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced results from the ongoing ARROW clinical trial showing durable respo...

Blueprint Medicines ( BPMC +3.4% ) has  reported new data from preclinical study of BLU-945, a precision therapy for patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). More news on: Blueprint Medicines Corporation, Healthcar...

CAMBRIDGE, Mass. , Sept. 17, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced preclinical proof-of-concept data for BLU-945, an investigatio...

So far this year, shares of Blueprint Medicines (NASDAQ: BPMC) haven't performed nearly as well as the company's research and development team. The company's already earned FDA approval for two new cancer drugs this year, but the stock is down about 17% this year. Is this a good biotech sto...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 08/7/2020. Please visit our Tracking Ole Andreas Halvorsen&...

FDA approves Blueprint’s GAVRETO for lung cancer Blueprint Medicines Corporation ( BPMC ) announced that the FDA has given its approval to GAVRETO for treating adult patients with metastatic rearranged during transfection fusion-positive non-small cell lung cancer. Blueprint is coll...